ESH AL 2018 | Minimal residual disease: a key determinant of ALL treatment response

Charles Mullighan

Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies according to initial treatment response. This risk-adapted approach to therapy has been shown to reduce the poor outcomes associated with high-risk subtypes of ALL. In this interview, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Children’s Research Hospital, Memphis, TN, highlights the importance of MRD monitoring and the new techniques that are being used to measure MRD in ALL patients, such as sequencing-based approaches. Recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter